| Pharmaceutical Information |
| Drug Name |
Agalsidase beta |
| Drug ID |
BADD_D00049 |
| Description |
Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]
Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] |
| Indications and Usage |
For treatment of Fabry's disease (alpha-galactosidase A deficiency) |
| Marketing Status |
Prescription |
| ATC Code |
A16AB04 |
| DrugBank ID |
DB00103
|
| KEGG ID |
D03228
|
| MeSH ID |
C459420
|
| PubChem ID |
52918379
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
58468-0041; 58468-0040 |
| Synonyms |
agalsidase beta | Fabrazyme |
|
| Chemical Information |
| Molecular Formula |
C50H78N4O14 |
| CAS Registry Number |
928659-70-5 |
| SMILES |
CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3
=C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
